- Home
- ADXN vs SBFM Comparison
ADXN vs SBFM Comparison
Compare ADXN & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- SBFM
- Stock Information
- Founded
- ADXN 2002
- SBFM 2006
- Country
- ADXN Switzerland
- SBFM United States
- Employees
- ADXN N/A
- SBFM N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- SBFM Health Care
- Exchange
- ADXN Nasdaq
- SBFM Nasdaq
- Market Cap
- ADXN 11.3M
- SBFM 3.7M
- IPO Year
- ADXN N/A
- SBFM N/A
- Fundamental
- Price
- ADXN $10.30
- SBFM $3.06
- Analyst Decision
- ADXN Strong Buy
- SBFM
- Analyst Count
- ADXN 1
- SBFM 0
- Target Price
- ADXN $30.00
- SBFM N/A
- AVG Volume (30 Days)
- ADXN 22.8K
- SBFM 121.6K
- Earning Date
- ADXN 11-11-2024
- SBFM 11-11-2024
- Dividend Yield
- ADXN N/A
- SBFM N/A
- EPS Growth
- ADXN N/A
- SBFM N/A
- EPS
- ADXN 0.05
- SBFM N/A
- Revenue
- ADXN $960,641.00
- SBFM $30,481,982.00
- Revenue This Year
- ADXN N/A
- SBFM $86.70
- Revenue Next Year
- ADXN N/A
- SBFM $126.76
- P/E Ratio
- ADXN $1.75
- SBFM N/A
- Revenue Growth
- ADXN N/A
- SBFM 109.82
- 52 Week Low
- ADXN $5.00
- SBFM $2.42
- 52 Week High
- ADXN $27.90
- SBFM $660.00
- Technical
- Relative Strength Index (RSI)
- ADXN 54.08
- SBFM 49.32
- Support Level
- ADXN $10.04
- SBFM $2.85
- Resistance Level
- ADXN $10.81
- SBFM $3.05
- Average True Range (ATR)
- ADXN 0.59
- SBFM 0.15
- MACD
- ADXN 0.04
- SBFM 0.02
- Stochastic Oscillator
- ADXN 70.88
- SBFM 63.89
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.